Injectable Stapokibart for seasonal allergies in teens
Treatments studied
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This study tests an injectable medication called Stapokibart for teenagers with seasonal allergies (hay fever). It aims to see if the drug can reduce allergy symptoms like sneezing, runny nose, and itchy eyes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old [missing: age <18]
- You weigh at least 40 kilograms (about 88 pounds)
- You have been diagnosed with seasonal allergic rhinitis (hay fever) for at least 2 years
- You may also have allergic conjunctivitis (eye allergies)
- You have not recently used other allergy treatments that would interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new biologic medicine (injection) to see if it can better control seasonal allergy symptoms in teens who haven't had good relief from standard treatments like nasal sprays.
This trial tests whether PL-14, a new nasal spray, works better than saline spray at relieving seasonal allergy symptoms like sneezing, itching, and congestion. If it works well and is safe, it could offer patients a new way to manage allergies during pollen season.
This study tests a new nasal spray (ALDP001) in adults with seasonal allergies to ragweed. It aims to find the best dose and how often to use it.
This study looks at how well an allergy injection called Stapokibart works for people with seasonal allergic rhinitis (hay fever). If you qualify, you'll receive the treatment as part of your normal care, and the study team will track your results.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
Hear when a new Seasonal Allergic Rhinitis (SAR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.